Dianthus Therapeutics (NASDAQ:DNTH) Given Buy Rating at Guggenheim

Guggenheim reissued their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH - Free Report) in a research note released on Wednesday morning,Benzinga reports. Guggenheim currently has a $84.00 target price on the stock.

A number of other research firms also recently weighed in on DNTH. Raymond James upgraded Dianthus Therapeutics to a "moderate buy" rating in a research report on Thursday, December 12th. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Finally, TD Cowen began coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They set a "buy" rating for the company. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $52.14.

Dianthus Therapeutics Stock Performance

DNTH traded down $0.62 on Wednesday, reaching $21.28. The company had a trading volume of 259,714 shares, compared to its average volume of 226,840. Dianthus Therapeutics has a 52-week low of $18.13 and a 52-week high of $33.77. The company has a market cap of $629.82 million, a price-to-earnings ratio of -8.51 and a beta of 1.82. The business has a 50 day simple moving average of $22.65 and a 200 day simple moving average of $24.94.

Remove Ads

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. As a group, equities research analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds have recently made changes to their positions in the business. MetLife Investment Management LLC boosted its holdings in Dianthus Therapeutics by 3.1% in the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company's stock valued at $313,000 after acquiring an additional 433 shares in the last quarter. Invesco Ltd. raised its stake in Dianthus Therapeutics by 7.4% in the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock worth $251,000 after buying an additional 790 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Dianthus Therapeutics by 9.2% in the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company's stock worth $210,000 after buying an additional 814 shares during the period. Barclays PLC grew its holdings in shares of Dianthus Therapeutics by 2.6% during the 4th quarter. Barclays PLC now owns 42,766 shares of the company's stock worth $933,000 after acquiring an additional 1,082 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Dianthus Therapeutics by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company's stock worth $3,641,000 after acquiring an additional 1,092 shares in the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.